BIOCEPT INC (BIOC)

US09072V6002 - Common Stock

0.4349  -0.07 (-13.05%)

After market: 0.39 -0.04 (-10.32%)

Full estimates are only available for subscribed users, you can see which data is available below.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2020 2021 2022 2023 2024 2025
Revenue
YoY % growth
27.46M
396.56%		61.249M
123.05%		25.858M
-57.78%		2.526M
-90.23%
EBITDA
YoY % growth
-14.38M
35.02%		-879K
93.89%		-30.328M
-3,350.28%		N/AN/AN/A
EBIT
YoY % growth
-15.47M
32.91%		-2.409M
84.43%		-31.983M
-1,227.65%		-24.438M
23.59%
Operating Margin
-56.34%-3.93%-123.69%-967.47%
EPS
YoY % growth
-1.89-0.10
94.71%		-43.07
-42,970.00%		-5.66
86.86%

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q3 / 23 Q4 / 23
EPS
Q2Q % growth		-2.78
71.87%
Revenue
Q2Q % growth		613.02K
-39.12%
EBITDA
Q2Q % growth		N/AN/A
EBIT
Q2Q % growth		-5.408M
46.76%

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2022
Q2Q % growth		 -32.70
-18,066.67%		-7.50-25.20-336.17%
Q3 2022
Q2Q % growth		 -9.90
-33,100.00%		-5.97-3.93-65.91%
Q2 2022
Q2Q % growth		 -0.31
-121.43%		-0.16-0.15-89.95%
Q1 2022
Q2Q % growth		 -0.16
-184.21%		-0.14-0.02-12.04%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q4 2022
Q2Q % growth		 25.858M
85.02%		3.331M22.527M676.28%
Q3 2022
Q2Q % growth		 1.007M
-94.24%		9.721M-8.714M-89.64%
Q2 2022
Q2Q % growth		 10.611M
-11.92%		12.723M-2.112M-16.60%
Q1 2022
Q2Q % growth		 19.945M
12.30%		11.72M8.225M70.18%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% N/A 0% 83.63%
Revenue0% N/A 0% -63.99%